Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 298

1.

High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma.

Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann SF.

Ann Surg. 2019 Aug 16. doi: 10.1097/SLA.0000000000003370. [Epub ahead of print]

PMID:
31425286
2.

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.

Kieler M, Unseld M, Bianconi D, Waneck F, Mader R, Wrba F, Fuereder T, Marosi C, Raderer M, Staber P, Berger W, Sibilia M, Polterauer S, Müllauer L, Preusser M, Zielinski CC, Prager GW.

ESMO Open. 2019 Jul 17;4(4):e000538. doi: 10.1136/esmoopen-2019-000538. eCollection 2019.

PMID:
31423337
3.

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations.

Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR.

Eur J Nucl Med Mol Imaging. 2019 Aug 13. doi: 10.1007/s00259-019-04452-y. [Epub ahead of print]

PMID:
31410538
4.

Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V, Weller M, van den Bent MJ, Wick W, Preusser M.

Neuro Oncol. 2019 Aug 1. pii: noz131. doi: 10.1093/neuonc/noz131. [Epub ahead of print]

PMID:
31369680
5.

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy.

Preusser M.

ESMO Open. 2019 Jul 5;4(Suppl 4):e000552. doi: 10.1136/esmoopen-2019-000552. eCollection 2019. No abstract available.

6.

How we treat glioblastoma.

Weller M, Le Rhun E, Preusser M, Tonn JC, Roth P.

ESMO Open. 2019 Jun 17;4(Suppl 2):e000520. doi: 10.1136/esmoopen-2019-000520. eCollection 2019. Review.

7.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

8.

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.

Lambertini M, Preusser M, Zielinski CC.

ESMO Open. 2019 Jun 12;4(Suppl 3):e000501. doi: 10.1136/esmoopen-2019-000501. eCollection 2019. No abstract available.

9.

Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling.

Furtner J, Oth I, Schöpf V, Nenning KH, Asenbaum U, Wöhrer A, Woitek R, Widhalm G, Kiesel B, Berghoff AS, Hainfellner JA, Preusser M, Prayer D.

Clin Neuroradiol. 2019 Jun 26. doi: 10.1007/s00062-019-00808-x. [Epub ahead of print]

PMID:
31263906
10.

How we treat patients with leptomeningeal metastases.

Le Rhun E, Preusser M, van den Bent M, Andratschke N, Weller M.

ESMO Open. 2019 May 21;4(Suppl 2):e000507. doi: 10.1136/esmoopen-2019-000507. eCollection 2019. Review.

11.

Quantitative evidence for early metastatic seeding in colorectal cancer.

Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C.

Nat Genet. 2019 Jul;51(7):1113-1122. doi: 10.1038/s41588-019-0423-x. Epub 2019 Jun 17.

PMID:
31209394
12.

DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.

Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, Zadeh G, Aldape KD; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jun 3. pii: noz061. doi: 10.1093/neuonc/noz061. [Epub ahead of print]

PMID:
31158293
13.

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Neuhauser M, Roetzer T, Oberndorfer S, Kitzwoegerer M, Payer F, Unterluggauer JJ, Haybaeck J, Stockhammer G, Iglseder S, Moser P, Thomé C, Stultschnig M, Wuertz F, Brandner-Kokalj T, Weis S, Bandke D, Pichler J, Hutterer M, Krenosz KJ, Boehm A, Mayrbaeurl B, Hager-Seifert A, Kaufmann H, Dumser M, Reiner-Concin A, Hoenigschnabl S, Kleindienst W, Hoffermann M, Dieckmann K, Kiesel B, Widhalm G, Marosi C, Jaeger U, Hainfellner A, Hackl M, Hainfellner JA, Preusser M, Woehrer A.

Acta Oncol. 2019 Jul;58(7):967-976. doi: 10.1080/0284186X.2019.1599137. Epub 2019 Apr 17.

PMID:
30994047
14.

Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?

Berghoff AS, Preusser M.

Nat Rev Neurol. 2019 Jun;15(6):314-315. doi: 10.1038/s41582-019-0178-0. No abstract available.

PMID:
30936570
15.

High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T.

Hangel G, Jain S, Springer E, Hečková E, Strasser B, Považan M, Gruber S, Widhalm G, Kiesel B, Furtner J, Preusser M, Roetzer T, Trattnig S, Sima DM, Smeets D, Bogner W.

Neuroimage. 2019 May 1;191:587-595. doi: 10.1016/j.neuroimage.2019.02.023. Epub 2019 Feb 14.

PMID:
30772399
16.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
17.

PET imaging in patients with brain metastasis-report of the RANO/PET group.

Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC.

Neuro Oncol. 2019 May 6;21(5):585-595. doi: 10.1093/neuonc/noz003.

PMID:
30615138
18.

High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases.

Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U, Nenning KH, Widhalm G, Kiesel B, Gatterbauer B, Dieckmann K, Birner P, Prayer D, Preusser M, Furtner J.

PLoS One. 2018 Nov 29;13(11):e0207849. doi: 10.1371/journal.pone.0207849. eCollection 2018.

19.

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS.

Clin Exp Metastasis. 2018 Dec;35(8):727-738. doi: 10.1007/s10585-018-9947-1. Epub 2018 Nov 12.

20.

Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma.

Handisurya A, Rumpold T, Caucig-Lütgendorf C, Flechl B, Preusser M, Ilhan-Mutlu A, Dieckmann K, Widhalm G, Grisold A, Wöhrer A, Hainfellner J, Ristl R, Kurz C, Marosi C, Gessl A, Hassler M.

Radiother Oncol. 2019 Jan;130:139-148. doi: 10.1016/j.radonc.2018.10.014. Epub 2018 Oct 30.

PMID:
30389240
21.

Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.

Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, Idoate Gastearena MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter PN, Felsberg J, Hänggi D, Herold-Mende C, Berghoff AS, Weller M, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A, Sahm F.

Acta Neuropathol. 2018 Dec;136(6):975-978. doi: 10.1007/s00401-018-1924-x. Epub 2018 Oct 31. No abstract available.

PMID:
30382370
22.

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C.

Cancers (Basel). 2018 Oct 5;10(10). pii: E372. doi: 10.3390/cancers10100372.

23.

Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin.

Yang D, Denny SK, Greenside PG, Chaikovsky AC, Brady JJ, Ouadah Y, Granja JM, Jahchan NS, Lim JS, Kwok S, Kong CS, Berghoff AS, Schmitt A, Reinhardt HC, Park KS, Preusser M, Kundaje A, Greenleaf WJ, Sage J, Winslow MM.

Cancer Discov. 2018 Oct;8(10):1316-1331. doi: 10.1158/2159-8290.CD-17-0987. Epub 2018 Sep 18.

PMID:
30228179
24.

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC.

ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018. Review. Erratum in: ESMO Open. 2019 Mar 11;4(2):e000368corr1.

25.

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.

Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, Furtner J, Sheffield NC, Datlinger P, Peter N, Nowosielski M, Augustin M, Mischkulnig M, Ströbel T, Alpar D, Ergüner B, Senekowitsch M, Moser P, Freyschlag CF, Kerschbaumer J, Thomé C, Grams AE, Stockhammer G, Kitzwoegerer M, Oberndorfer S, Marhold F, Weis S, Trenkler J, Buchroithner J, Pichler J, Haybaeck J, Krassnig S, Mahdy Ali K, von Campe G, Payer F, Sherif C, Preiser J, Hauser T, Winkler PA, Kleindienst W, Würtz F, Brandner-Kokalj T, Stultschnig M, Schweiger S, Dieckmann K, Preusser M, Langs G, Baumann B, Knosp E, Widhalm G, Marosi C, Hainfellner JA, Woehrer A, Bock C.

Nat Med. 2018 Oct;24(10):1611-1624. doi: 10.1038/s41591-018-0156-x. Epub 2018 Aug 27.

PMID:
30150718
26.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

PMID:
30137421
27.

Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma.

Jenkinson MD, Weber DC, Haylock BJ, Sherratt FC, Young B, Weller M, Bulbeck H, Culeddu G, Hughes DA, Brain A, Das K, Preusser M, Francis P, Gamble C.

J Neurosurg. 2018 Oct;129(4):1104-1105. doi: 10.3171/2018.6.JNS181418. Epub 2018 Aug 17. No abstract available.

28.

Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression.

Huang RY, Unadkat P, Bi WL, George E, Preusser M, McCracken JD, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2019 Feb 14;21(2):234-241. doi: 10.1093/neuonc/noy126.

PMID:
30085283
29.

New developments in brain metastases.

Berghoff AS, Preusser M.

Ther Adv Neurol Disord. 2018 Jun 28;11:1756286418785502. doi: 10.1177/1756286418785502. eCollection 2018. Review.

30.

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Schöpf V, Reumann R, Pascher B, Woitek R, Asenbaum U, Pelster S, Leitner J, Widhalm G, Gatterbauer B, Dieckmann K, Höller C, Prayer D, Preusser M.

J Neurooncol. 2018 Oct;140(1):173-178. doi: 10.1007/s11060-018-2948-8. Epub 2018 Jul 14.

31.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C; International Immuno-Oncology Biomarker Working Group.

Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157. doi: 10.1016/j.semcancer.2018.07.001. Epub 2018 Jul 7. Review.

PMID:
29990622
32.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
33.

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF.

Oncoimmunology. 2018 Mar 13;7(6):e1435226. doi: 10.1080/2162402X.2018.1435226. eCollection 2018.

34.

5-ALA-induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients.

Kiesel B, Millesi M, Woehrer A, Furtner J, Bavand A, Roetzer T, Mischkulnig M, Wolfsberger S, Preusser M, Knosp E, Widhalm G.

Neurosurg Focus. 2018 Jun;44(6):E7. doi: 10.3171/2018.3.FOCUS1859.

PMID:
29852770
35.

Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?

Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, Preusser M, Saba L.

Crit Rev Oncol Hematol. 2018 Jun;126:135-144. doi: 10.1016/j.critrevonc.2018.03.026. Epub 2018 Apr 7. Review. No abstract available.

PMID:
29759556
36.

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G.

Histopathology. 2018 Oct;73(4):573-584. doi: 10.1111/his.13646. Epub 2018 Jul 4.

PMID:
29742291
37.

Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.

Wolpert F, Weller M, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, Roth P, Reyns N, Kaufmann PA, Preusser M, Le Rhun E.

Eur J Cancer. 2018 Jun;96:64-72. doi: 10.1016/j.ejca.2018.03.010. Epub 2018 Apr 17.

PMID:
29677642
38.

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.

Mir Seyed Nazari P, Riedl J, Preusser M, Posch F, Thaler J, Marosi C, Birner P, Ricken G, Hainfellner JA, Pabinger I, Ay C.

J Thromb Haemost. 2018 Jun;16(6):1121-1127. doi: 10.1111/jth.14129. Epub 2018 May 20.

39.

Anti-angiogenic therapies in brain metastases.

Berghoff AS, Preusser M.

Memo. 2018;11(1):14-17. doi: 10.1007/s12254-018-0384-2. Epub 2018 Feb 2. Review.

40.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

41.

The Evolving Landscape of Brain Metastasis.

Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffietti R.

Trends Cancer. 2018 Mar;4(3):176-196. doi: 10.1016/j.trecan.2018.01.003. Epub 2018 Feb 21. Review.

42.

MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas.

Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, Schoppmann SF.

J Cancer. 2018 Jan 1;9(3):460-468. doi: 10.7150/jca.22310. eCollection 2018.

43.

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction.

Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, Schoppmann SF.

Oncotarget. 2018 Jan 8;9(6):6968-6976. doi: 10.18632/oncotarget.24087. eCollection 2018 Jan 23.

44.

Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.

Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, Tonn JC, Zielinski C.

ESMO Open. 2018 Jan 26;3(1):e000262. doi: 10.1136/esmoopen-2017-000262. eCollection 2018. Review.

45.

Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.

Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Teoh EJ, Bottomley D, Scarsbrook A, Payne H, Afaq A, Bomanji J, van As N, Chua S, Hoskin P, Chambers A, Cook GJ, Warbey VS, Chau A, Ward P, Miller MP, Stevens DJ, Wilson L, Gleeson FV, Scheidhauer K, Seidl C, Autenrieth M, Bruchertseifer F, Apostolidis C, Kurtz F, Horn T, Pfob C, Schwaiger M, Gschwend J, D'Alessandria C, Morgenstern A, Uprimny C, Kroiss A, Decristoforo C, von Guggenberg E, Nilica B, Horninger W, Virgolini I, Rasul S, Poetsch N, Woehrer A, Preusser M, Mitterhauser M, Wadsak W, Widhalm G, Mischkulnig M, Hacker M, Traub-Weidinger T, Wright CL, Binzel K, Wuthrick EJ, Miller ED, Maniawski P, Zhang J, Knopp MV, Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L, Mairinger S, Filip T, Sauberer M, Flunkert S, Wanek T, Stanek J, Okamura N, Langer O, Kuntner C, Fornito MC, Balzano R, Di Martino V, Cacciaguerra S, Russo G, Seifert D, Kleinova M, Cepa A, Ralis J, Hanc P, Lebeda O, Mosa M, Vandenberghe S, Mikhaylova E, Borys D, Viswanath V, Stockhoff M, Efthimiou N, Caribe P, Van Holen R, Karp JS, Binzel K, Zhang J, Wright CL, Maniawski P, Knopp MV, Haller PM, Farhan C, Piackova E, Jäger B, Knoll P, Kiss A, Podesser BK, Wojta J, Huber K, Mirzaei S, Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Sibilia M, Langer O, Fornito MC, Russello M, Russo G, Balzano R, Sorko S, Gallowitsch HJ, Kohlfuerst S, Matschnig S, Rieser M, Sorschag M, Lind P, Ležaič L, Rep S, Žibert J, Frelih N, Šuštar S, Binzel K, Adelaja A, Wright CL, Scharre D, Zhang J, Knopp MV, Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, Kulkarni HR, Fornito MC, Cacciaguerra S, Balzano R, Di Martino GV, Russo G, Thomson WH, Kudlacek M, Karik M, Farhan C, Rieger H, Pokieser W, Glaser K, Mirzaei S, Petz V, Tugendsam C, Buchinger W, Schmoll-Hauer B, Schenk IP, Rudolph K, Krebs M, Zettinig G, Zoufal V, Wanek T, Krohn M, Mairinger S, Stanek J, Sauberer M, Filip T, Pahnke J, Langer O, Weitzer F, Pernthaler B, Salamon S, Aigner R, Koranda P, Henzlová L, Kamínek M, Váchalová M, Bachleda P, Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom JN, Orlova A, Tolmachev V, Decristoforo C, Kaeopookum P, Summer D, Orasch T, Lechner B, Petrik M, Novy Z, Rangger C, Haas H, Decristoforo C.

EJNMMI Res. 2018 Jan 23;8(Suppl 1):5. doi: 10.1186/s13550-017-0354-4. No abstract available.

46.

Role of the blood-brain barrier in metastatic disease of the central nervous system.

Berghoff AS, Preusser M.

Handb Clin Neurol. 2018;149:57-66. doi: 10.1016/B978-0-12-811161-1.00004-9. Review.

PMID:
29307361
47.

Advances in meningioma genetics: novel therapeutic opportunities.

Preusser M, Brastianos PK, Mawrin C.

Nat Rev Neurol. 2018 Feb;14(2):106-115. doi: 10.1038/nrneurol.2017.168. Epub 2018 Jan 5. Review.

PMID:
29302064
48.

Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.

Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, Hejna M, Birner P, Preusser M.

Cancer Biol Ther. 2018 Mar 4;19(3):169-174. doi: 10.1080/15384047.2017.1414759. Epub 2018 Jan 17.

49.

Glioma Survival Prediction with Combined Analysis of In Vivo 11C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning.

Papp L, Pötsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M, Mitterhauser M, Kiesel B, Wadsak W, Beyer T, Hacker M, Traub-Weidinger T.

J Nucl Med. 2018 Jun;59(6):892-899. doi: 10.2967/jnumed.117.202267. Epub 2017 Nov 24.

50.

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.

Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonneterre J.

Eur J Cancer. 2017 Dec;87:189-198. doi: 10.1016/j.ejca.2017.10.006. Epub 2017 Nov 2.

Supplemental Content

Loading ...
Support Center